Phase 3 Readout
BSPM: Phase 3 Topline: A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Com
September 1, 2030 · utidelone. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2030
- Company
- BIOSTAR PHARMACEUTICALS, INC. (BSPM)
- Drug
- utidelone
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Com
- Drug
- utidelone
- Indication
- Gastric or Gastroesophageal Junction Adenocarcinoma